Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AM E3-SG3249
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
IRBM to Present Efficacy of Preclinical Agents Against Brain Tumors at AACR
Details : AM E3-SG3249, is a CRLF2/TLSP inhibitor, a preclinical candidate which is being investigated for the treatment of philadelphia chromosome-like acute lymphoblastic leukemia.
Brand Name : AM E3-SG3249
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 04, 2024
Lead Product(s) : AM E3-SG3249
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The collaboration aims to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 12, 2023
Lead Product(s) : Peptide Therapy
Therapeutic Area : Genetic Disease
Study Phase : Discovery
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
IRBM Extends Peptide Therapeutics Collaboration with Merck & Co. Inc., Rahway NJ USA
Details : The collaboration aims to evaluate the opportunities for peptide-based therapeutic candidates across multiple indications through the well-established phage and mRNA display platforms.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
June 22, 2023
Lead Product(s) : Peptide Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Antios Therapeutics
Deal Size : $50.0 million
Deal Type : Acquisition
Details : Under the agreement, Antios will purchase the IP rights to a novel series of fourth-generation capsid assembly modulators (CAMs) which is being developed for the treatment of HBV.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Antios Therapeutics
Deal Size : $50.0 million
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
IRBM to Collaborate with MSD to Develop Peptides Against Coronavirus
Details : IRBM will leverage previous research into SARS to contribute to identifying and developing a potential treatment of SARS-CoV-2, as well as other future life-threatening coronavirus strains.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
July 21, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?